Dermatology Times' Monthly Crossword: September 2025

Welcome to Dermatology Times' Monthly Crossword, where dermatology knowledge meets fun! Each month, we curate a selection of words and terms pulled directly from the latest news in the dermatology world. Whether it's breakthrough treatments, new research findings, or emerging trends, this crossword serves as both a challenge and an opportunity to reinforce your expertise in the field.

For more in-depth insights, don't forget to check out our Weekly Roundup, where we break down the most important stories and updates from the past week. And to stay ahead of the curve and prepare for future crosswords, make sure to follow our content throughout the month.

Try out either our interactive crossword or a static/non-interactive version below.

Interactive Crossword

This crossword was created with CrosswordLabs.com.

Static/Non-Interactive Crossword

Across

3. Conference brand providing advanced NP/PA dermatology education, held in Nashville Fall 2025.

5. Occupational dermatosis classically seen in health care workers with repeated allergen exposure.

8. Histamine-independent chronic dermatosis, often presenting as spontaneous wheals and angioedema.

10. Scarring alopecia subtype discussed by Jerry Shapiro.

11. Pathophysiologic “triad” in AD targeted by TRIV-509: barrier dysfunction, inflammation, and ___.

13. Significant biomarker category targeted by KT-621 in AD, beyond IL-4/IL-13 axis.

14. Conference presentation highlighted “judicious use” of this kind of testing in pediatric dermatology.

Down

1. Agent that achieved PASI 0 in nearly half of patients at year 4 in long-term psoriasis data at EADV.

2. Photo-induced eruption abbreviated PMLE.

4. Biologic combining IL-13 and IL-17A/F targeting moderate-to-severe atopic dermatitis discussed at EADV.

6. At the Maui Derm NP+PA Fall 2025 Conference, this cream was shown effective for acne-induced post-inflammatory hyperpigmentation in patients with skin of color.

7. “Forever chemicals” class under discussion for prenatal exposure and AD risk.

9. In EADV data, what drug maintained safety profile over 24 weeks in AD when targeting OX40 receptor?

12. Serum biomarker of Th2 inflammation significantly reduced by BBT001.

15. Adaptive immune effector cell central to psoriasis pathophysiology via IL-17 production.